| P50 | author | Carlo Buonerba | Q55188046 |
| | Vittorina Zagonel | Q56925944 |
| | Giuseppe Lucarelli | Q43136586 |
| P2093 | author name string | Sabino De Placido | |
| | Davide Bosso | |
| | Giuseppe Di Lorenzo | |
| | Guru Sonpavde | |
| | Davide Dondi | |
| | Sergio Bracarda | |
| | Donatello Gasparro | |
| | Angela Gernone | |
| | Caterina Messina | |
| | Livio Puglia | |
| P2860 | cites work | Poor survival in prostate cancer patients with primary refractoriness to docetaxel. | Q54630661 |
| | Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation | Q85847286 |
| | Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme | Q95522892 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 |
| | Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer | Q33390463 |
| | Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer | Q36353291 |
| | Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study | Q37703409 |
| | New perspectives in the therapy of castration resistant prostate cancer. | Q38050162 |
| | Peg-filgrastim and cabazitaxel in prostate cancer patients. | Q38050328 |
| | Castration-resistant prostate cancer: latest evidence and therapeutic implications | Q38233358 |
| | Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer | Q38919065 |
| | Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. | Q39205202 |
| | Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. | Q39411127 |
| | Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports | Q40820466 |
| | Beyond ten cycles of cabazitaxel for castrate-resistant prostate cancer | Q41706221 |
| | Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice | Q43004667 |
| | Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms | Q44647997 |
| | Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma | Q49134863 |
| | Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. | Q51052339 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e2299 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer | |
| P478 | volume | 95 | |